行情

CYCCP

CYCCP

Cyclacel Pharms
NASDAQ

实时行情|Nasdaq Last Sale

4.510
0.000
0.00%
已收盘, 16:00 11/15 EST
开盘
--
昨收
5.13
最高
--
最低
--
成交量
--
成交额
--
52周最高
7.00
52周最低
3.870
市值
151.21万
市盈率(TTM)
-7.6596
分时
5日
1月
3月
1年
5年

CYCCP 新闻

  • 欧股收高结束两连跌 整周录得连续第六周上涨
  • 新浪美股.2小时前
  • 收盘:美股再创新高 道指首次跨越28000点里程碑
  • 新浪美股.3小时前
  • 周五美油期货收高1.7% 布油上涨1.6%
  • 新浪美股.3小时前
  • 分析师:某位投资大佬可能正在“嗅探”Netflix
  • 新浪财经.3小时前

更多

所属板块

生物技术和医学研究
+1.49%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

CYCCP 简况

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
展开

Webull提供Cyclacel Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。